SG11201703806XA - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number
SG11201703806XA
SG11201703806XA SG11201703806XA SG11201703806XA SG11201703806XA SG 11201703806X A SG11201703806X A SG 11201703806XA SG 11201703806X A SG11201703806X A SG 11201703806XA SG 11201703806X A SG11201703806X A SG 11201703806XA SG 11201703806X A SG11201703806X A SG 11201703806XA
Authority
SG
Singapore
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
SG11201703806XA
Other languages
English (en)
Inventor
Heike Keilhack
Brett Truitt
Yuta Suzuki
Tsukasa Murase
Futoshi Shikata
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Publication of SG11201703806XA publication Critical patent/SG11201703806XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201703806XA 2014-11-17 2015-11-17 Method for treating cancer SG11201703806XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (1)

Publication Number Publication Date
SG11201703806XA true SG11201703806XA (en) 2017-06-29

Family

ID=56014476

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703806XA SG11201703806XA (en) 2014-11-17 2015-11-17 Method for treating cancer

Country Status (22)

Country Link
US (2) US10786511B2 (he)
EP (2) EP4272742A1 (he)
JP (3) JP6829684B2 (he)
KR (3) KR20240035908A (he)
CN (2) CN107249591B (he)
AU (3) AU2015350108B2 (he)
BR (1) BR112017010166A2 (he)
CA (1) CA2967664A1 (he)
DK (1) DK3220916T3 (he)
EA (1) EA201791095A1 (he)
ES (1) ES2947819T3 (he)
FI (1) FI3220916T3 (he)
HU (1) HUE062159T2 (he)
IL (3) IL296080B2 (he)
LT (1) LT3220916T (he)
MX (2) MX2017006089A (he)
NZ (1) NZ731696A (he)
PL (1) PL3220916T3 (he)
PT (1) PT3220916T (he)
SG (1) SG11201703806XA (he)
SI (1) SI3220916T1 (he)
WO (1) WO2016081523A1 (he)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
HUE062158T2 (hu) 2014-06-17 2023-10-28 Epizyme Inc EZH2 inhibitorok a limfóma kezelésére
PL3220916T3 (pl) 2014-11-17 2023-08-14 Epizyme, Inc. Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem
MX2017013142A (es) 2015-04-20 2019-03-28 Epizyme Inc Terapia combinada para tratar cáncer.
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
IL307260A (he) 2015-08-24 2023-11-01 Epizyme Inc שיטה לטיפול בסרטן
AU2017211331A1 (en) 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
JP2019521988A (ja) 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤
KR20190105602A (ko) 2017-01-19 2019-09-17 다이이찌 산쿄 가부시키가이샤 Htlv-1 관련 척수증을 치료하는 것에 사용하기 위한 의약 조성물
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
WO2018223030A1 (en) 2017-06-02 2018-12-06 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
CN115175904A (zh) * 2019-12-20 2022-10-11 Epizyme股份有限公司 Ezh2抑制剂的结晶氢溴酸盐、其制备和用于治疗癌症的药物组合物
JP2022167451A (ja) 2021-04-23 2022-11-04 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
KR102061353B1 (ko) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130296325A1 (en) * 2011-01-14 2013-11-07 Bristol-Myers Squibb Company HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
ES2951688T3 (es) 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
CA3177515A1 (en) 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
SG11201406468YA (en) * 2012-04-13 2015-01-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
WO2013155464A1 (en) * 2012-04-13 2013-10-17 Epizyme, Inc. Combination therapy for treating cancer
PE20150886A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
HUE046790T2 (hu) * 2012-10-15 2020-03-30 Epizyme Inc A rák kezelésének módszerei
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
SG10201901977XA (en) * 2013-10-16 2019-04-29 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
US20160228447A1 (en) 2013-10-18 2016-08-11 Epizyme, Inc. Method of treating cancer
WO2015085325A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
HUE062158T2 (hu) * 2014-06-17 2023-10-28 Epizyme Inc EZH2 inhibitorok a limfóma kezelésére
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
JP2017532338A (ja) 2014-10-16 2017-11-02 エピザイム，インコーポレイティド 癌を治療する方法
PL3220916T3 (pl) 2014-11-17 2023-08-14 Epizyme, Inc. Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem
EP3307713A4 (en) * 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
JP2019521988A (ja) * 2016-06-17 2019-08-08 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤

Also Published As

Publication number Publication date
IL296080B1 (he) 2023-08-01
KR102338802B1 (ko) 2021-12-14
AU2015350108A1 (en) 2017-05-25
JP7485810B2 (ja) 2024-05-16
MX2021006734A (es) 2021-07-02
CN107249591B (zh) 2024-01-30
HUE062159T2 (hu) 2023-10-28
ES2947819T3 (es) 2023-08-21
KR20240035908A (ko) 2024-03-18
PT3220916T (pt) 2023-06-26
SI3220916T1 (sl) 2023-09-29
NZ731696A (en) 2024-03-22
AU2021204706B2 (en) 2023-11-23
DK3220916T3 (da) 2023-06-26
FI3220916T3 (fi) 2023-06-19
IL304252A (he) 2023-09-01
CN116650500A (zh) 2023-08-29
JP6829684B2 (ja) 2021-02-10
IL296080A (he) 2022-11-01
US20210060030A1 (en) 2021-03-04
CA2967664A1 (en) 2016-05-26
EP3220916A4 (en) 2018-07-11
JP2021073241A (ja) 2021-05-13
KR102644844B1 (ko) 2024-03-07
IL252182A0 (he) 2017-07-31
KR20170103768A (ko) 2017-09-13
WO2016081523A1 (en) 2016-05-26
CN107249591A (zh) 2017-10-13
IL252182B2 (he) 2023-02-01
US20170360797A1 (en) 2017-12-21
KR20210156840A (ko) 2021-12-27
IL252182B (he) 2022-10-01
EP3220916A1 (en) 2017-09-27
AU2021204706A1 (en) 2021-07-29
US10786511B2 (en) 2020-09-29
IL296080B2 (he) 2023-12-01
AU2015350108B2 (en) 2021-04-08
EP3220916B1 (en) 2023-04-19
LT3220916T (lt) 2023-07-25
JP2017537899A (ja) 2017-12-21
BR112017010166A2 (pt) 2018-02-14
PL3220916T3 (pl) 2023-08-14
JP2023062189A (ja) 2023-05-02
EA201791095A1 (ru) 2017-10-31
EP4272742A1 (en) 2023-11-08
AU2024201171A1 (en) 2024-03-14
MX2017006089A (es) 2017-12-11

Similar Documents

Publication Publication Date Title
IL304252A (he) שיטות לטיפול בסרטן
HK1251407A1 (zh) 治療癌症的方法
ZA201706616B (en) Method for treating cancer
IL289947A (he) שיטה לטיפול בסרטן
EP3110509A4 (en) Method for treating cancer
IL257691A (he) שיטה לטיפול בסרטן
HK1244217A1 (zh) 用於治療蛋白質病的方法
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
SG11201607130RA (en) Combination method for treatment of cancer
HK1250944A1 (zh) 用於治療癌症的方法
HK1248135A1 (zh) 用於治療癌症的聯合方法
HK1250942A1 (zh) 用於治療癌症的方法
IL246558A0 (he) שיטות חדשות לטיפול בסרטן
HK1250943A1 (zh) 用於治療癌症的方法
ZA201608820B (en) Method for treating drug resistant cancer
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (zh) 用於治療腫瘤的方法